Transperitoneal administration of dissolved hydrogen for peritoneal dialysis patients: a novel approach to suppress oxidative stress in the peritoneal cavity

Hiroyuki Terawaki1, Yoshimitsu Hayashi2, Wan-Jun Zhu3, Yukie Matsuyama4, Tomoyoshi Terada4, Shigeru Kabayama3, Tsuyoshi Watanabe2, Seiichi Era4, Bunpei Sato5 and Masaaki Nakayama1,2,3*

Abstract

Background: Oxidative stress (OS) related to glucose degradation products such as methylglyoxal is reportedly associated with peritoneal deterioration in patients treated with peritoneal dialysis (PD). However, the use of general antioxidant agents is limited due to their harmful effects. This study aimed to clarify the influence of the novel antioxidant molecular hydrogen (H2) on peritoneal OS using albumin redox state as a marker.

Methods: Effluent and blood samples of 6 regular PD patients were obtained during the peritoneal equilibrium test using standard dialysate and hydrogen-enriched dialysate. The redox state of albumin in effluent and blood was determined using high-performance liquid chromatography.

Results: Mean proportion of reduced albumin ($\xi$(HMA)) in effluent was significantly higher in H2-enriched dialysate (62.31 ± 11.10%) than in standard dialysate (54.70 ± 13.08%). Likewise, serum $\xi$(HMA) after administration of hydrogen-enriched dialysate (65.75 ± 7.52%) was significantly higher than that after standard dialysate (62.44 ± 7.66%).

Conclusions: Trans-peritoneal administration of H2 reduces peritoneal and systemic OS.

Keywords: Trans-peritoneal administration of H2 reduces peritoneal and systemic OS.

Background

Peritoneal deterioration is one of the most serious complications of peritoneal dialysis (PD) therapy, leading to ultrafiltration failure and the more severe complication of encapsulating peritoneal sclerosis (EPS). As the duration of PD increases, so does the risk of peritoneal deterioration [1]. More than 40% of patients in Japan who were on PD treatment for longer than 8 years stopped treatment due to the progression of peritoneal damage [2]. The pathological mechanisms of peritoneal damage are multi-factorial, but accumulated data have revealed the critical role of glucose degradation end-products (GDPs), i.e., chemically reactive carbonyl compounds. Methylglyoxal (MG) is one of the representative toxic GDPs, causing detrimental effects due to its rapid and indiscriminate oxidative nature [3], and its production of toxic reactive oxygen species (ROS) such as hydroxyl radical, methyl radical, and undetermined carbon-centered radicals [4]. These used to be present in conventional dialysate, and also enter into the dialysate from uremic plasma [5]. Bio-compatible low-GDP dialysate is currently available, but a Japanese multicenter nationwide study, the NEXT-PD study [6], revealed the occurrence of EPS even with the use of low-GDP solutions [under submission]. This indicates the need for novel therapeutic approaches to suppress possible insults from enhanced oxidative stress (OS) due to uremic oxidants in the peritoneal cavity.
Recently, the novel role of molecular hydrogen (H\textsubscript{2}) as an antioxidant has been revealed. H\textsubscript{2} eliminates the hydroxyl radical in cultured cells and living organisms [7]. Interestingly, H\textsubscript{2} does not influence other ROS, including superoxide, peroxide, and nitric oxide; these ROS play important physiological roles in body [8]. In humans, the safety of H\textsubscript{2} has been tested, particularly in the field of deep diving. In contrast to general drugs, which usually have some harmful effects, no toxicity was found even at high concentrations of H\textsubscript{2} [9]. H\textsubscript{2} thus has therapeutic potential for pathological states related to ROS [10].

The present study tested the effects of peritoneal dialysate containing a high concentration of molecular hydrogen (H\textsubscript{2}-enriched dialysate) as a novel anti-oxidant among patients treated with PD. As a result, we demonstrated that the use of hydrogen-enriched dialysate could reduce not only peritoneal, but also systemic OS in clinical settings.

**Methods**

**Preparation of hydrogen-enriched dialysate**

Hydrogen-enriched dialysate was prepared using MiZ nondestructive hydrogen dissolver (MiZ, Kanagawa, Japan), as reported elsewhere [11]. When commercial peritoneal dialysate is immersed in H\textsubscript{2}-enriched water, hydrogen permeates through the container, resulting in the H\textsubscript{2} concentration of dialysate gradually increasing in a time-dependent manner (Figure 1). We prepared H\textsubscript{2}-enriched dialysate using this apparatus by immersing commercial peritoneal dialysate bags for more than 2 hr. Hydrogen-enriched dialysate was then applied as a test solution for peritoneal equilibrium testing.

**Patients**

Six male PD patients were studied (mean age, 55 years; range, 44–71 years; length of PD, 39 ± 17 months; weight, 68.1 ± 16.1 kg; height, 166.2 ± 5.6 cm). The pathology underlying end-stage renal disease was as follows: chronic glomerulonephritis, n = 3; diabetic nephropathy, n = 2; and hypertensive nephropathy, n = 1. Patients with active infection, bleeding, liver dysfunction, collagen disease, systemic vasculitis, cardiovascular accident within 6 months, or malignancy were excluded from this study. Performance status of all patients was class 1 according to American Heart Association criteria [12]. All patients had been receiving daily continuous ambulatory

*Figure 1* MiZ nondestructive hydrogen dissolver (A) and the hydrogen concentration of peritoneal dialysate in hydrogen-saturated water (B). Hydrogen concentration of dialysate and hydrogen-saturated water around dialysate was measured using a dissolved H\textsubscript{2} measurement apparatus DH-35A (DKK-TOA, Tokyo, Japan).
PD (3–4 bags/day) using neutral low-GDP dextrose solution. The ethics committee of Fukushima Medical University approved this study protocol (Acceptance No. 1362) and written informed consent was obtained from all patients prior to enrollment.

**Protocol**

Patients underwent a simplified peritoneal equilibration test (fast PET) using standard dialysate, then underwent fast PET using hydrogen-enriched dialysate 2 weeks later. Fast PET was conducted in accordance with the method of Twardowski [13]. In brief, peritoneal dialysate (2 L of 2.5% dextrose-dialysate) was intraperitoneally infused with a Tenckhoff catheter, and the entire volume of dialysate was drained from the body after 240 min. The drained effluent was mixed well and 2 mL was collected as an effluent sample. Blood samples were obtained before and after fast PET, then 2 mL of serum was drawn after centrifugation and stored at −80°C for 1–4 weeks until analysis. Samples of serum and effluent collected to measure albumin redox were stored at −80°C for 1–4 weeks until analysis. During fast PET, blood pressure, cardiac pulse, and hydrogen concentration in the breath were measured repeatedly every 60 min. Breath hydrogen concentration was also measured in three cases just after, 15 min after, and 30 min after infusion of H2-enriched dialysate. Breath hydrogen concentration was measured using a biological gas (gas in the oral cavity) H2 measurement apparatus BGA-1000D (Aptec, Waltham, MA, USA). A Shodex-Asahipak ES-502N 7C column (10 × 0.76 cm L.D., DEAE-form for ion-exchange HPLC; Showa Denko, Tokyo, Japan; column temperature, 35 ± 0.5°C) was used in this study. Elusion was performed as linear gradient elusion with graded ethanolic concentrations (0 to 1 min, 0%; 1 to 50 min, 0→10%; 50 to 55 min, 10→0%; 55 to 60 min, 0%) for serum in 0.05 M sodium acetate and 0.40 M sodium sulfate mixture (pH 4.85) at a flow rate of 1.0 mL/min. De-aeration of the buffer solution was performed by bubbling helium.

HPLC profiles obtained from these procedures were subjected to numerical curve fitting with PeakFit version 4.05 simulation software (SPSS Science, Chicago, IL, USA), and each peak shape was approximated by a Gaussian function. Values for fractions of HMA, HNA-1, and HNA-2 to total HSA were then calculated \((f(HMA))\), \((f(HNA-1))\), and \((f(HNA-2))\), respectively.

**Statistical analysis**

Values are expressed as mean ± standard deviation unless otherwise stated. StatView version 5.0 statistical software (SAS Institute, Cary, NC, USA) was used for statistical analysis. The significance of collected data was evaluated using a paired \(t\)-test or 1-factor repeated-measures analysis of variance (ANOVA) followed by Scheffe's test as a post-hoc test, as appropriate. For magnitude of correlation, Pearson's correlation coefficient was used.

**Table 1** The changes of blood pressure, cardiac pulse, and breath H2 concentration during fast PET

| Blood pressure (mmHg) | Standard dialysate | H2-enriched dialysate |
|-----------------------|--------------------|-----------------------|
| 0 min                 | 130 ± 12 / 79 ± 10 | 135 ± 13 / 81 ± 10    |
| 60 min                | 130 ± 11 / 79 ± 5  | 131 ± 14 / 82 ± 12    |
| 120 min               | 125 ± 9 / 79 ± 7   | 134 ± 8 / 80 ± 14     |
| 180 min               | 123 ± 12 / 75 ± 12 | 136 ± 5 / 78 ± 12     |
| 240 min               | 128 ± 9 / 78 ± 7   | 132 ± 9 / 81 ± 13     |

| Pulse (1/min)         | Standard dialysate | H2-enriched dialysate |
|-----------------------|--------------------|-----------------------|
| 0 min                 | 81 ± 7             | 82 ± 12               |
| 60 min                | 76 ± 6             | 79 ± 12               |
| 120 min               | 74 ± 6             | 78 ± 14               |
| 180 min               | 77 ± 4             | 78 ± 17               |
| 240 min               | 78 ± 7             | 81 ± 15               |

| Breath H2 ppm         | Standard dialysate | H2-enriched dialysate |
|-----------------------|--------------------|-----------------------|
| 0 min                 | 4.7 ± 6.6          | 3.2 ± 20              |
| 60 min                | 1.8 ± 1.3          | 8.3 ± 7.5*            |
| 120 min               | 3.0 ± 1.7          | 8.5 ± 11.0            |
| 180 min               | 4.2 ± 2.8          | 5.8 ± 48              |
| 240 min               | 5.5 ± 6.7          | 7.2 ± 46              |

\* \( p < 0.05\) vs. standard dialysate.
(R) was used. Differences or correlations were considered significant for values of $P < 0.05$.

**Results**

Table 1 shows changes in blood pressure, heart rate, and breath hydrogen concentration during fast PET. Regarding blood pressure and heart rate, no significant difference was seen between standard and H$_2$-enriched dialysate (paired t-test). No significant changes were observed during fast PET in either standard or H$_2$-enriched dialysate (1-factor repeated-measures ANOVA).

Changes in breath hydrogen concentration in all cases are shown in Table 1 and Figure 2 (A, B). Although no significant changes were observed during fast PET in both standard and H$_2$-enriched dialysate, the hydrogen concentration at 60 min was significantly higher in H$_2$-enriched dialysate than in standard dialysate.

Breath hydrogen concentrations before, just after, 15 min after, and 30 min after administration of H$_2$-enriched dialysate in three cases are shown in Figure 2C. Hydrogen concentrations just after and 15 min after administration were significantly higher than before administration.

![Figure 2 Change in breath hydrogen concentration during fast PET. A) Hourly change in PET using standard dialysate. No significant changes were observed. B) Hourly change during PET using H$_2$-enriched dialysate. The hydrogen concentration at 60 min was significantly higher in H$_2$-enriched dialysate than in standard dialysate. C) Breath hydrogen concentrations before, just after, 15 min after, and 30 min after administration of H$_2$-enriched dialysate in three cases. Hydrogen concentrations just after and 15 min after administration were significantly higher than that before administration.](image-url)
significantly higher in H₂-enriched dialysate (62.31 ± 11.10%) than in standard dialysate (54.70 ± 13.08%). Like \( f(HNA-1) \), \( f(HNA-2) \) was significantly lower in H₂-enriched dialysate (34.26 ± 10.24%) than in standard dialysate (34.94 ± 11.13%). These results suggest that the use of H₂-enriched dialysate reduced peritoneal OS. Regarding the result of fast PET (D/P-Cre, drained volume) and effluent creatinine, albumin, interleukin 6 and carbohydrate antigen 125 levels, no differences were evident between standard and H₂-enriched dialysate (Table 2).

Figure 4 shows the redox state of albumin in serum before and after fast PET. The serum \( f(HMA) \) level after administration of H₂-enriched dialysate (65.75 ± 7.52%) was significantly higher than that after standard dialysate (62.44 ± 7.66%). In contrast, \( f(HNA-1) \) after administration of H₂-enriched dialysate (31.12 ± 6.73%) was significantly lower than that of standard dialysate (34.23 ± 7.02%). These results suggest that use of H₂-enriched dialysate reduced not only peritoneal, but also systemic OS. No significant difference was seen between effluent and serum \( f(HMA) \) levels after administration of H₂-enriched dialysate (65.31 ± 11.10% and 62.71 ± 7.52%, respectively), while effluent \( f(HMA) \) after administration of standard dialysate was significantly lower than serum \( f(HMA) \) before administration of standard dialysate (54.70 ± 13.08% and 62.96 ± 8.34%, respectively; \( P = 0.0339 \)), suggesting that intraperitoneal oxidation of albumin was suppressed by H₂-enriched dialysate.

**Discussion**

Several reports have suggested that OS participates in peritoneal deterioration, with findings such as strong cytoplasmic staining of 8-hydroxy-2’-deoxyguanosine in peritoneal biopsy specimens of long-term PD patients [15], amplified protein kinase C signaling and fibronectin expression due to enhanced ROS in cultured human mesothelial cells [16]. In terms of the central role of enhanced OS in PD peritoneal damage, Gunal et al. [17] showed that oral supplementation with the anti-oxidative agent trimetazidine inhibited morphological and functional deterioration of the peritoneum in a PD rat model. However, regarding suppressing OS, no clinical approaches have been available for PD treatment so far.

The present study aimed to test the therapeutic possibility of using dissolved hydrogen in the dialysate to suppress intra-cavity OS in the clinical setting. This study examined the redox state of albumin as a marker of OS. Since the change in redox state of albumin is a physiological and direct reaction, it is appropriate when evaluating real-time OS and/or detecting rapid changes in OS, as compared to other OS markers such as 8-hydroxy-2’-deoxyguanosine, oxidized low-density lipoprotein and F2 isoprotanes, all of
which are in vivo by-products during the process of oxidation.

This pilot study of 6 patients clearly demonstrated that single administration of H2-enriched dialysate increased levels of both peritoneal and plasma \(f(HMA)\) without any detrimental effects.

Intraperitoneal administration of H2 altered the local redox state, which may indicate the therapeutic potential of delivering H2 directly to the abdominal cavity in respect to the amelioration of peritoneal damage by PD treatment. On the other hand, interestingly, significant increases in serum \(f(HMA)\) levels were seen on intraperitoneal administration of H2. Rapid changes in hydrogen concentration of expired gas after the administration of H2-enriched dialysate may mean that molecular hydrogen in dialysate is rapidly distributed to the body to suppress systemic OS. Another possibility is that increased \(f(HMA)\) in the cavity may be recruited into systemic circulation through the abdominal lymphatic drainage. The exact mechanisms underlying increased serum \(f(HMA)\) need to be addressed in the future.

In addition, the mechanisms of increased \(f(HMA)\) and decreased \(f(HMA1)\) by H2 have remained unclear in this study. However, molecular hydrogen is known to directly reduce levels of the cytotoxic hydroxyl radical [7], through several possible mechanisms, such as regulation of particular metalloproteins by bonding, or metalloprotein-hydrogen interactions [18]. Whether H2 directly reacts with the mercapto-residue of albumin, or H2 indirectly modifies it, should be clarified in the future.

Satisfactory anti-oxidative capability of drinking H2-enriched water without any detrimental effects has been reported, in both experimental [19-23] and clinical settings, e.g., type II diabetes mellitus [24], metabolic syndrome [25], myopathies (progressive muscular dystrophy and polymyositis/dermatomyositis) [26], and rheumatoid arthritis [27]. In addition, we also reported the clinical feasibility of applying H2-enriched water as dialysate for hemodialysis treatment [28,29]. Given these reports and our present findings, H2-enriched peritoneal dialysate could be of interest in clinical trials with respect to peritoneal preservation. Furthermore, therapeutic effects seem plausible in terms of the prevention of cardiovascular events in patients, since low \(f(HMA)\) has been a significant risk factor for cardiovascular mortality among patients treated with PD [30] and HD [14].

In summary, single administration of H2-enriched dialysate reduced peritoneal and systemic OS without any detrimental effects. A longitudinal study is warranted to ensure clinically beneficial effects, such as suppression of peritoneal deterioration and cardiovascular damage.

### Table 2 The results of serum creatinine value, fast PET and effluent test

| Parameter                  | Standard dialysate | H2-enriched dialysate |
|----------------------------|--------------------|------------------------|
| Creatinine mg/dL           | 10.53 ± 2.27       | 10.03 ± 2.19          |
| Parameter of fast PET      |                    |                        |
| D/P-Cre                   | 0.71 ± 0.12        | 0.66 ± 0.11           |
| Drained volume mL/4 hr     | 470 ± 184          | 442 ± 130             |
| Effluent test              |                    |                        |
| Albumin mg/L               | 408 ± 175          | 402 ± 145             |
| Interleukin-6 pg/mL        | 6.0 ± 3.3          | 5.5 ± 2.3             |
| CA125 U/mL                 | 18.8 ± 8.5         | 19.5 ± 5.0            |

![Figure 4 Redox state of albumin in serum before and after fast PET](image-url)

**A** The mean proportion of reduced albumin \(f(HMA)\) was significantly higher after fast PET using H2-enriched dialysate than after using standard dialysate (A). Conversely, the mean proportion of reversibly oxidized albumin \(f(HMA1)\) was significantly lower after fast PET using H2-enriched dialysate than that after using standard dialysate (B). No significant changes were found in irreversibly oxidized albumin \(f(HMA2)\) in the both groups (C).
Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
HT, YH, and WJZ carried out the selections of patients, and the sample collections. HT drafted the manuscript. YM, TT, and SE carried out the measurements of samples. SK, and TW contributed to the study as senior advisors. BS carried out the set-up of equipment system for study. MN organized the study project, and drafted the final manuscript. All authors read and approved the final manuscript.

Author details
1Dialysis Centre, Fukushima Medical University, Fukushima, Japan. 2Department of Nephrology, Hypertension, Diabetes, Endocrinology, and Metabolism, Fukushima Medical University, Fukushima, Japan. 3Center for Advanced and Integrated Renal Science, Tohoku University Graduate School of Medicine, Sendai, Japan. 4Department of Physiology and Biophysics, Gifu University Graduate School of Medicine, Gifu, Japan. 5Miz Company, Kanagawa, Japan.

Received: 16 March 2013 Accepted: 12 June 2013 Published: 1 July 2013

References
1. Yamamoto R, Otsuka Y, Nakayama M, Maruyama Y, Katoch N, Ikeda M, Yamamoto H, Yokoyama K, Kawaguchi Y, Matsuhashi M: Risk factors for encapsulating peritoneal sclerosis in patients who have experienced peritoneal dialysis treatment. Clin Exp Nephrol 2005, 9:148–152.
2. Kawaguchi Y, Ishiaki T, Imada A, Oshira S, Kurijama S, Nakamoto H, Nakamoto M, Hiransat M, Maeda K, Ota K: Study Group for Withdrawal from PD in Japan: Searching for the reasons for drop-out from peritoneal dialysis: a nationwide survey in Japan. Pent Dial Int 2003, 23 (Suppl 25):157–177.
3. Glomb MA, Monnier MV: Mechanism of protein modification by glyoxal and glycoaldehyde, reactive intermediates of the Maillard reaction. J Biol Chem 1995, 270:10017–10026.
4. Nakayama M, Saito K, Sato E, Nakayama K, Terawaki H, Ito S, Kohno M: Radical generation by the non-enzymatic reaction of methylglyoxal and hydrogen peroxide. Redox Rep 2007, 12:125–135.
5. Terawaki H, Nakao M, Nakayama K, Nakayama M, Kimura A, Takane K, Mitome J, Hamaguchi A, Ogura M, Yokoyama K, Ito S, Hotta T: Peritoneal clearance and transport of methylglyoxal. Nephrol Dial Transplant 2011, 26:753–754.
6. Kawanishi H, Nakayama M, Miyazaki M, Honda K, Tomo K, Kasi K, Nakamoto H: NEXT-PD Study Group: Prospective multicenter observational study of encapsulating peritoneal sclerosis with neutral dialysis solution – the NEXT-PD study. Adv Pent Dial 2010, 26:71–74.
7. Ohswana I, Ishikawa M, Takahashi K, Watanabe Y, Ishikawa H, Kuriyama S, Nakamoto H, Nakamura M, Hiramatsu M, Maeda K, Ota K: Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals. Nip Med 2007, 18:686–694.
8. Abraim JH, Gardette-Chaussier MC, Marteau E, Rostain JC, Lemaire C: Psychophysiological reactions in humans during an open sea dive to 500 m with a hydrogen-helium-oxygen mixture. J Appl Physiol 1994, 76:1113–1118.
9. Fontanari P, Badier M, Guillot C, Tomel C, Burnet H, Gardette B, Jammes Y: Changes in maximal performance of inspiratory and skeletal muscles during and after the 7.1-MPa Hydra 10 record human dive. Eur J Appl Physiol 2000, 81:325–328.
10. Ohta S: Recent progress toward hydrogen medicine: potential of molecular hydrogen for preventive and therapeutic applications. Curr Pharm Des 2011, 17:2241–52.
11. Abe T, Li XX, Yazawa K, Hatayama N, Xie L, Sato B, Kikuta Y, Tatsuhara K, Okumi M, Tsuda H, Kaimon JR, Isaka Y, Naito N, Takahara S, Nonomura N: Hydrogen-rich University of Wisconsin solution attenuates renal cold ischemia-reperfusion injury. Transplantation 2012, 94:14–21.
12. American Heart Association: Criteria for the evaluation of the severity of established renal disease: Report of the council on the kidney in cardiovascular diseases. Circulation 1971, 44:306–307.
13. Twardowski ZJ: PET—a simpler approach for determining prescriptions for adequate dialysis therapy. Adv Pent Dial 1990, 6:186–191.

14. Terawaki H, Takada Y, Era S, Funakoshi Y, Nakayama K, Nakayama M, Ogura M, Ito S, Hosoy A: The redox state of albumin and serious cardiovascular incidence in hemodialysis patients. Ther Apher Dial 2010, 14:465–471.
15. Ishibashi T, Sugimoto T, Ishikawa Y, Akatsuka A, Miyata T, Nakanari K, Tagawa H, Kurokawa K: Glucose dialyse induces mitochondrial DNA damage in peritoneal mesothelial cells. Perit Dial Int 2002, 22:11–21.
16. Lee HB, Yu MR, Song JS, Ha H: Reactive oxygen species amplify protein kinase C signaling in high glucose-induced fibrocin expression by human peritoneal mesothelial cells. Kidney Int 2004, 65:1170–1179.
17. Gural AL, Celiker H, Ugunduz B, Akpolat N, Akciokk F: The effect of oxidative stress inhibition with trimetazidine on the peritoneal alterations induced by hypertonic peritoneal dialysis solution. J Nephrol 2002, 15:225–300.
18. Shi P, Sun W, Shi P: A hypothesis on chemical mechanism of the effect of hydrogen. Med Gas Res 2012, 217.
19. Ohsawa I, Nishimaki K, Yamagata K, Ishikawa M, Ohta S: Consumption of hydrogen water prevents atherosclerosis in apolipoprotein E knockout mice. Biochem Biophys Res Commun 2008, 377:1195–1198.
20. Sato Y, Kajiyama S, Amano A, Kondo Y, Saisi T, Handa S, Takahashi R, Fukui M, Hasegawa G, Nakamura N, Fujishiro H, Mori T, Ohta M, Obayashi H, Miyamoto N, Ishigami A: Hydrogen-rich pure water prevents superoxide formation in brain slices of vitamin C-depleted SMP30/GNL knockout mice. Biochem Biophys Res Commun 2008, 357:346–350.
21. Nakashima-Kaminura N, Moti T, Ohsawa I, Asch S, Ohta S: Molecular hydrogen alleviates nephrotic syndrome induced by anti-cancer drug cisplatin without compromising anti-tumor activity in mice. Cancer Chemother Pharmacol 2009, 64:753–761.
22. Cardinal JS, Zhan J, Wang Y, Sugimoto R, Tsung A, McCurry KR, Billar TR, Nakao A: Oral hydrogen water prevents chronic otalgia nephropathy in rats. Kidney Int 2010, 77:101–109.
23. Zhu WJ, Nakayama M, Mori T, Nakayama K, Katoch J, Murata Y, Sato T, Kabayama S, Ito S: Intake of water with high levels of dissolved hydrogen (H2) suppresses ischemia-induced cardio-renal injury in Dahl salt-sensitive rats. Nephrol Dial Transplant 2011, 26:2112–2118.
24. Kajiyama S, Hasegawa G, Anano M, Hosoda H, Fukui M, Nakamura N, Kitawaki J, Imai S, Nakano K, Ohta M, Adachi T, Obayashi H, Yoshishika T: Supplementation of hydrogen-rich water improves lipid and glucose metabolism in patients with type 2 diabetes or impaired glucose tolerance. Nutr Res 2008, 28:137–143.
25. Nakao A, Toyoda Y, Sharma P, Evans M, Guthrie N: Effectiveness of hydrogen rich water on antioxidant status of subjects with potential metabolic syndrome – an open label pilot study. J Clin Biochem Nutr 2010, 46:140–149.
26. Ito M, Ikeda T, Sahashi K, Ishihara M, Ko M, Ohno K: Open-label trial and randomized, double-blind, placebo-controlled crossover trial of hydrogen-enriched water for mitochondrial and inflammatory myopathies. Med Gas Res 2011, 1:24.
27. Ishibashi T, Sato B, Rikatake M, Seo T, Kurokawa R, Hara Y, Narimani Y, Hara H, Nagao T: Consumption of water containing a high concentration of molecular hydrogen reduces oxidative stress and disease activity in patients with rheumatoid arthritis: an open-label pilot study. Med Gas Res 2012, 2:27.
28. Nakayama M, Kabayama S, Nakano H, Zhu WJ, Terawaki H, Nakayama K, Katoch K, Satoh T, Ito S: Biological effect of electrolyzed water in hemodialysis. Nephron Clin Pract 2009, 112:c9–15.
29. Nakayama M, Nakano H, Hamada H, Irami N, Nakazawa R, Ito S: A novel bioactive haemodialysis system using dissolved dihydrogen (H2) produced by water electrolysis: a clinical trial. Nephrol Dial Transplant 2010, 25:3026–3033.
30. Terawaki H, Matsuura Y, Matsuo N, Ogura M, Mitome J, Hamaguchi A, Terada T, Era S, Hosoy A: A lower level of reduced albumin induces serious cardiovascular incidence among peritoneal dialysis patients. Clin Exp Nephrol 2012, 16:569–635.

Cite this article as: Terawaki et al.: Transperitoneal administration of dissolved hydrogen for peritoneal dialysis patients: a novel approach to suppress oxidative stress in the peritoneal cavity. Medical Gas Research 2013 3:14.